Cancer and Immunotherapy · global
From Tumor Sequencing to Personalized Vaccines: India’s PopVax Launches mRNA Cancer Vaccine Manufacturing Service
Making a vaccine for each patient involves more than identifying cancer cell markers; it also requires timely, consistent manufacturing. PopVax proposes delivery within eight to ten weeks, but its cancer vaccines have not yet been used in humans, and their efficacy and safety remain to be established in clinical trials.
Each cancer patient’s tumor has different mutations. Turning these differences into signals the immune system can recognize could offer another treatment option. However, moving from tumor data to a personalized vaccine requires design, manufacturing, and quality testing. Indian biotechnology company PopVax is attempting to integrate this process into a service. What it has announced so far is development and manufacturing capability; there are no human treatment results for its personalized cancer vaccines yet.
PopVax has partnered with Stochastic Sciences to establish the RNA Foundry in Hyderabad to design and produce personalized mRNA cancer vaccines. The company says it has the capacity to make more than 100 personalized cancer vaccines over the next twelve months. Most projects are estimated to cost approximately US$300,000 and take eight to ten weeks, with actual timelines depending on manufacturing availability. These figures are the company’s service estimates and should not be taken as the cost of a complete course of treatment or a guaranteed timeframe within which a patient can obtain a vaccine.
Design begins with tumor sequencing data: the team looks for neoantigens that mutations may produce—abnormal protein fragments that the immune system may recognize—and then encodes instructions for making the selected markers into mRNA. According to the company, its computational workflow combines AI models with tools that predict antigen presentation and immunogenicity to help screen candidate markers. However, a prediction that a marker can be recognized does not mean it will necessarily trigger a response strong enough to control cancer in a patient.
The mRNA is then encapsulated in lipid nanoparticles and delivered after manufacturing, filling, and quality testing. PopVax claims its proprietary lipid formulation can remain stable for more than nine months at two to eight degrees Celsius. If this applies to individual products, it could ease cold-chain requirements. However, storage stability and formulation quality require a different level of validation from the ability to shrink tumors or prolong survival.
Clinical evidence remains the most critical gap in this initiative. An interview published by The New Indian Express on November 2 noted that these cancer vaccine candidates had not yet been administered to patients at that time. Although PopVax has advanced a COVID-19 vaccine candidate using the same mRNA and lipid platform into human trials, the cancer vaccines must still establish evidence of safety and efficacy through their own clinical trials.
Founder Soham Sankaran told the newspaper that the initial plan was to work with a small number of physicians and patients outside India, aiming to provide vaccines before the end of the year through pathways such as individual patient applications or compassionate use, subject to the relevant regulatory permissions. These access pathways do not constitute marketing approval. The company also positions the vaccines as a supplement to existing cancer treatments.
The RNA Foundry offers a framework for moving personalized vaccines from computational design to actual manufacturing. What ultimately determines their medical value will be whether the selected antigens can drive an effective immune response in humans, and whether that response can translate into tangible treatment benefits for patients. Production capacity and delivery speed make the concept more concrete; clinical trials will determine whom it can help.